COMMUNICATION:
MyoD Functions as a Transcriptional Repressor in Proliferating Myoblasts*

(Received for publication, October 17, 1996, and in revised form, December 6, 1996)

Caryn Chu , John Cogswell Dagger and D. Stave Kohtz §

From the Department of Pathology, Mount Sinai School of Medicine, New York, New York 10029 and the Dagger  Department of Cellular Sciences, Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The myogenic basic helix-loop-helix (myo-bHLH) proteins are a family of transcriptional regulators expressed in myoblasts and differentiated skeletal muscle. Ectopic expression of myo-bHLH regulators transdetermines some fibroblast cell lines into myoblasts, which exit the cell cycle and differentiate into skeletal muscle when cultured in low mitogen medium. While members of the myo-bHLH family have been shown to function as transcriptional activators in differentiating muscle, the molecular basis of their function in proliferating myoblasts has not been elucidated. In this report, we present evidence that MyoD functions as a transcriptional repressor in myoblasts. We show that transcription from a cyclin B1 promoter construct is repressed in proliferating myoblasts and that repression is mediated by a pair of MyoD binding sites. We also show that transcription from the cyclin B1 promoter is repressed in proliferating C3H10T1/2 cells by ectopic expression of MyoD. These results demonstrate that MyoD can repress transcription of specific genes in proliferating cells, a novel function that may be important to maintenance of the myogenic phenotype and to cell cycle regulation in myoblasts.


INTRODUCTION

Cells committed to the myogenic lineage are referred to as myoblasts, and the stability of this phenotype is evident after several passages in culture (1). The development and differentiation of competent myoblasts is dependent on expression of the myogenic basic helix-loop-helix (myo-bHLH)1 regulators (2-7). Four myo-bHLH regulators have been identified (MyoD, myogenin, myf-5, MRF4/myf-6/herculin; Refs. 8-13), and ectopic expression of any one will confer the myoblast phenotype to C3H10T1/2 fibroblasts (8, 14). The myo-bHLH regulators appear to perform two functions in myogenic cells: conferral and maintenance of the myogenic phenotype in proliferating myoblasts and activation of muscle gene transcription in differentiated muscle cells. Activation of muscle gene transcription by myo-bHLH regulators has been well studied and is contingent on the removal or depletion of mitogenic stimuli and withdrawal from the cell cycle (15-18). In contrast, myo-bHLH regulators confer the myogenic phenotype to mitogenic cells, even though they appear to be inert as activators of transcription in this cellular context.

Myogenic bHLH regulators isolated from myoblasts blocked from differentiation by high serum or transforming growth factor beta  display significant site-specific DNA-binding activity in electrophoretic mobility shift assays (19). Inhibition of muscle gene transcription by these mitogens involves redundant mechanisms that include sequestering of E proteins by protein Id (20) and binding of certain members of the Jun family (21, 22). Inhibition of myo-bHLH regulators by bFGF also may involve redundant mechanisms. Stimulation of protein kinase C by bFGF may block the activity of some myogenic bHLH regulators through phosphorylation of a conserved threonine in the basic regions of these proteins (23). Treatment of myoblasts with bFGF also has been shown to stimulate expression of cyclin D1 (24). Cyclin D1-dependent kinase activity inhibits the activity of the myo-bHLH regulators through a mechanism that may involve phosphorylation of sites in the activation domains of these proteins2 (25, 26). Although activation of most muscle-specific genes by the myo-bHLH regulators is blocked in myoblasts, autoactivation of transcription from the myo-bHLH regulator genes is not inhibited. The mechanisms of transcriptional activation of the myo-bHLH genes are not well understood, and the role of MyoD in autoactivation may involve an indirect mechanism. Indeed, recent evidence has suggested that direct binding of myo-bHLH regulators to the upstream regions of these genes is not required for autoactivation (27).

Functional complexes of the B-type cyclins and p34CDC2/CDK1 are necessary for entry into and progression through mitosis (28-30). Two B-type cyclins (B1 and B2) have been identified in mammals (31) that differ in subcellular distribution (32). Accumulation of B-type cyclins and cyclin B-p34CDC2/CDK1 kinase activity during the G2, G2/M, and M phases of the cell cycle is regulated by several mechanisms. Proteolysis of B-type cyclins in late M phase occurs after ubiquitination (33), and the subcellular location of B-type cyclins also changes dramatically during different phases of the cell cycle. In addition, transcription of B-type genes is strongly induced during late S and G2 phases (31).

The structure and sequence of the cyclin B1 promoter has been described (34, 35). Two consensus binding sites for MyoD and one for products of the E2A gene were identified upstream of a basal promoter (36-38). Since the cyclin B1 gene is active in proliferating rather than terminally differentiated cells, this promoter presented an opportunity to study the effects of MyoD on gene transcription in proliferating myoblasts. In this report, we show that the paired MyoD binding sites in the cyclin B1 promoter mediate repression of cyclin B1 gene transcription in proliferating C2C12 myoblasts. Ectopic expression of MyoD in proliferating C3H10T1/2 cells also repressed the cyclin B1 reporter. Evidence that both MyoD binding sites function in concert to mediate repression is presented. These results reveal a novel function for MyoD in proliferating myoblasts as a specific transcriptional repressor.


MATERIALS AND METHODS

Plasmid Constructs

Deletion mutant constructs, pCycB1(-3800)-CAT, pCycB1(-1050)-CAT, pCycB1(-290)-CAT, and pCycB1(-290 USF Mut)-CAT have been described previously (34). pCycB1(-318)-CAT and pCycB1(-169)-CAT were made by deleting fragments between StuI sites at -318 or -169 and the polylinker HindIII site of pCycB1(-1050)-CAT. pCycB1(-224)-CAT was generated by deleting the PstI-PstI fragment from pCycB1(-1050)-CAT. pCycB1(-127)-CAT was created by subcloning the XmnI to XbaI fragment of pCycB1(-1050)-CAT into SmaI-XbaI sites of pBluescript KS+ (Stratagene). Then, the fragment was excised with HindIII and XbaI and cloned into respective sites of pCAT-Basic (Promega). Site mutant construct, pCycB1(-290 MyoD 5' Mut)-CAT was made by engineering a MluI site at the 5' MyoD binding sequence. pCycB1(-290 MyoD 3' Mut)-CAT was also made by engineering an EcoRI site at the 3' MyoD binding sequence. pCycB1(-290 MyoD [5' + 3'] Mut)-CAT was generated by engineering both MluI and EcoRI sites at the 5' and 3' MyoD binding sites. pRSV-CAT (39) was given by E. Johnson (Mount Sinai Medical School). pEMSV-MyoD and pEMSV-alpha 2 were provided by A. Lassar (Harvard Medical School) and H. Weintraub (Fred Hutchinson Cancer Research Center).

Transient Expression Assays

C2C12 myoblasts (40) were grown in high mitogen medium (Dulbecco's modified Eagle's medium supplemented with 15% fetal bovine serum (HyClone) and 0.5% chick embryo extract (Life Technologies, Inc.)). C3H10T1/2 fibroblasts were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cells were grown to 50% confluency and transfected using a standard calcium phosphate precipitate protocol (41). After 18 h with the precipitate, new medium was added, and cells were harvested for CAT activity 16 h later. CAT assays were performed as described (42). Equal protein levels were determined by the Bradford assay. CAT activities were quantitated by phosphorimage analysis of thin layer chromatography plates. Baseline activity of pCAT-Basic was determined from transfections with pCAT-Basic and pEMSV-alpha 2. One hundred percent activity was determined from transfections with either pCycB1(-318)-CAT or pCycB1(-290)-CAT and pEMSV-MyoD. The values were normalized to parallel transient expression assays performed with a Rous sarcoma virus long terminal repeat expression construct (pRSV-CAT).


RESULTS

Repression of the Cyclin B1 Gene Minimal Promoter in C2C12 Myoblasts

The cyclin B1 minimal promoter has recently been identified, and analysis of its sequence has revealed consensus binding sites for several transcriptional regulators upstream of the transcription initiation site (34). Binding sites for AP-2 (-181 to -174; Refs. 43 and 44), SP1 (-263 to -258 and -144 to -139; Refs. 45-48), NF-Y (-49 to -42; Refs. 49 and 50), MyoD (-268 to -263 and -236 to -231; Refs. 36 and 51), USF (-190 to -185; Refs. 52 and 53), and E2A gene products (-224 to -218; Refs. 54-57) have been identified (Fig. 1A). A series of deletion mutants of the cyclin B1 promoter (-3800, -1050, -318, -224, -169, and -127; Fig. 1B) were assayed for activity as CAT reporter constructs in proliferating C2C12 myoblasts (the promoter displayed only low level activity in differentiated myotubes; data not shown). Of these constructs, pCycB1(-224)-CAT displayed the greatest transcriptional activity. The activity of pCycB1(-169)-CAT and pCycB1(-127)-CAT was significantly less than that of pCycB1(-224)-CAT, due to the loss of an essential USF binding site (Fig. 1B; Refs. 34 and 53). Interestingly, retention of the pair of MyoD binding sites in constructs pCycB1(-318)-CAT, pCycB1(-1050)-CAT, and pCycB1(-3800)-CAT resulted in repression of transcription in comparison to pCycB1(-224)-CAT. Since it is expressed at significant levels in C2C12 myoblasts (8), this result suggested to us that MyoD may mediate transcriptional repression of certain genes in proliferating myoblasts.


Fig. 1. Deletion mutant analysis of repression of the cyclin B1 promoter in proliferating C2C12 myoblasts. A, structural maps of deletion mutants of the cyclin B1 promoter. The positions of consensus binding site for MyoD (8, 37, 38), SP1 (45-48), E2A gene products (36, 54), USF (52, 53), AP-2 (43, 44), and NF-Y (49, 50) are shown. The sizes are determined by their distances from the transcription initiation site, which is indicated with an arrow. B, 10 µg of each deletion mutant was transfected as a CAT reporter construct into proliferating C2C12 myoblasts and assayed for transcriptional activity. The highest transcriptional activity was observed for pCycB1(-224)-CAT, which lacks the MyoD consensus binding sites. CAT activities of each reporter construct were normalized to CAT activities obtained with pRSV-CAT. Mean values and standard error from three independent transfection experiments are shown.
[View Larger Version of this Image (20K GIF file)]


Paired MyoD Binding Sites Are Required for Repression of the Cyclin B1 Promoter

We next asked whether the MyoD binding sites specifically mediate repression of the pCycB1-CAT constructs, and whether both sites or a single site are required for this function. Single-base mutants eliminating the left (pCycB1(-290 5' MyoDmut)-CAT), right (pCycB1(-290 3' MyoDmut)-CAT), or both (pCycB1(-290 [5' + 3'] MyoDmut)-CAT) MyoD binding sites were tested for expression in C2C12 myoblasts. Expression was compared to that of a wild-type construct (pCycB1(-290)-CAT) spanning the same promoter region (this construct contains the paired MyoD binding sites; Fig. 2A). Expression of all three mutant reporter constructs greatly exceeded that of the wild-type construct (Fig. 2B). Thus, mutation of either MyoD binding site abolishes repression of the pCycB1-CAT reporters in proliferating myoblasts. This result strongly suggests that binding to these sites is required for repression. Interestingly, disruption of either site blocked repression, indicating that repression requires binding to both sites.


Fig. 2. Site mutant analysis of the role of paired MyoD binding sites in repression of the cyclin B1 promoter in C2C12 myoblasts. A, structural maps of the MyoD binding site mutants. The sequences of the disrupted E-box sequences are shown. The reporter plasmid pCycB1(-290)-CAT is identical to pCycB1(-318)-CAT, except that it lacks 28 nucleotides 5' to the left (5') MyoD binding site. B, 10 µg of each site mutant was transfected as a CAT reporter construct into proliferating C2C12 myoblasts and assayed for transcriptional activity. Disruption of either MyoD binding site eliminates repression of the cyclin B1 promoter. CAT activities of each reporter construct were normalized to CAT activities obtained with pRSV-CAT. Mean values and standard error from three independent transfection experiments are shown.
[View Larger Version of this Image (22K GIF file)]


Ectopic Expression of MyoD Mediates Repression of the Cyclin B1 Promoter in C3H10T1/2 Fibroblasts

We next asked whether repression of transcription from the pCycB1-CAT reporters is mediated by MyoD expression. The mouse fibroblast cell line C3H10T1/2 was transfected with pCycB1(-127)-CAT, pCycB1(-169)-CAT, pCycB1(-224)-CAT, and pCycB1(-318)-CAT either with or without a MyoD expression construct (pEMSV-MyoD). The transient expression assays were performed with C3H10T1/2 cells under mitogenic conditions (subconfluence in high serum medium). Under these conditions, activation of muscle gene transcription by ectopic MyoD is inhibited as it is in myoblasts cultured similarly. Expression of pCycB1(-127)-CAT, pCycB1(-169)-CAT, and pCycB1(-224)-CAT in proliferating C3H10T1/2 fibroblasts was either unaffected or stimulated by ectopic expression of MyoD (Fig. 3). In contrast, ectopic expression of MyoD inhibited expression of pCycB1(-318)-CAT, consistent with the presence of the paired MyoD binding sites on this construct. This result shows that MyoD can directly mediate repression of the minimal cyclin B1 reporter through interaction with the paired binding sites present in pCycB1(-318)-CAT. Interestingly, repression of pCycB1(-318)-CAT by ectopic expression of MyoD was not observed in CV-1 cells (data not shown), which are resistant to myogenic conversion (58).


Fig. 3. Ectopic expression of MyoD mediates repression of the cyclin B1 promoter in proliferating C3H10T1/2 cells. 5 µg of each deletion mutant (described in Fig. 1A (pCycB1(-318, -224, -169, -127)-CAT) was transfected as a CAT reporter construct into proliferating C3H10T1/2 fibroblasts with either pEMSValpha 2 (-MD) or pEMSV-MyoD (+MD) and assayed for CAT activity. Mean values and standard error from three independent transfection experiments are shown.
[View Larger Version of this Image (32K GIF file)]


The role of the paired MyoD binding site in mediating repression by MyoD was further investigated by transient expression assays of pCycB1(-290)-CAT site mutants in proliferating C3H10T1/2 cells. Ectopic expression of MyoD repressed pCycB1(-290)-CAT in proliferating C3H10T1/2 cells only when both binding sites were intact (Fig. 4). Indeed, disruption of the right (3') or both binding sites resulted in stimulation of pCycB1(-290)-CAT by ectopic expression of MyoD (Fig. 4). These results are consistent with those obtained using the same mutants in C2C12 myoblasts and emphasize the functional importance of both binding sites in mediating repression by MyoD. Disruption of other E-box sequences (including the USF site) in the pCycB1-CAT constructs does not affect repression (data not shown).


Fig. 4. Site mutants of pCycB1(-290)-CAT are resistant to repression by ectopic expression of MyoD. 5 µg of each site mutant described in Fig. 2A (pCycB1(-290 MyoD 5' Mut, MyoD 3' Mut, MyoD [5' + 3'] Mut)-CAT) was transfected as a CAT reporter construct into proliferating C3H10T1/2 fibroblasts with either pEMSValpha 2 (-MD) or pEMSV-MyoD (+MD), and assayed for CAT activity. Mean values and standard error from three independent transfection experiments are shown.
[View Larger Version of this Image (20K GIF file)]



DISCUSSION

The possibility that E-box binding proteins may function as transcriptional repressors has been suggested by studies of the immunoglobulin heavy chain (IgH) enhancer. The activity of a bHLH protein (TFE3) that binds a µE3 site in the IgH enhancer is repressed by binding of another factor to an adjacent µE5 site (59). Displacement of the repressor factor by another µE5-binding protein (ITF-1) has been shown to mediate activation of the IgH enhancer (59). The IgH enhancer contains E-box sequences that can bind MyoD; however, binding of MyoD to these sites does activate transcription (36, 60). Repression of transcriptional activation of the IgH enhancer by MyoD is also dependent on an adjacent µE5 site; removal of this site allows MyoD to activate transcription from the mutant enhancer (61). The protein(s) binding µE5 site(s) in the IgH enhancer and repressing transcriptional activation by adjacent E-box binding proteins have not been characterized as yet. Nonetheless, a functional parallel may be drawn to repression of the cyclin B1 promoter by MyoD, which may result from repression of transcriptional activation by USF. In support of this possibility, specific binding of the cyclin B1 promoter by USF has been shown to be required for transcriptional activation (34).

Although ectopic expression of MyoD in fibroblasts can induce autoactivation of the endogenous MyoD gene and activate expression of other myo-bHLH regulators, the molecular basis of these events is not clear. Electrophoretic gel mobility shift assays suggest that MyoD maintains significant sequence-specific DNA binding activity in myoblasts (36, 38, 62). On the other hand, activation of muscle gene transcription by all of the myo-bHLH regulators is restricted to mitogenically arrested cells. Repression of the transcriptional activity of the myo-bHLH regulators in proliferating cells has been well studied (63), and recent studies of autoactivation of the MyoD gene in myoblasts have supported an indirect mechanism (27). Binding of MyoD to its own promoter is not required for autoactivation in myoblasts, consistent with its lack of transcriptional activity in mitogenically active cells. As shown here, the repressor activity of MyoD is functional in proliferating myoblasts. From this observation, an indirect mechanism of autoactivation can be proposed in which the expression of a repressor of MyoD gene transcription is itself repressed by MyoD.

Understanding the role of MyoD in regulating expression of the cyclin B1 gene during the cell cycle will require further investigation. Similar to activation of the IgH enhancer by TFE3 described above, activation of the cyclin B1 gene by USF and/or downstream elements may require displacement of MyoD by another factor. The activity and/or expression of the displacing factor may be restricted to the G2 and M phases of the cell cycle, when expression of the cyclin B1 gene is maximal. Recent studies by Hwang et al. (35) have suggested that binding of inhibitory protein(s) to a region -90 to +1 of the cyclin B1 promoter represses transcription during late G1. In addition, their studies show that repression of the cyclin B1 promoter during G1 is mediated by a region between -207 and -872, which we show here contains the binding sites that confer repression by MyoD. It is possible that in other cell types functionally analogous repressor proteins are expressed that bind the same E-box sites as MyoD in the cyclin B1 promoter. Experiments are in progress to test this hypothesis.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: Dept. of Pathology (1194), Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. Tel.: 212-241-9169; Fax: 212-534-7491.
1    The abbreviations used are: bHLH, basic helix-loop-helix; bFGF, basic fibroblast growth factor; USF, upstream stimulatory factor; CAT, chloramphenicol acetyltransferase.
2    C. Chu, J. Molkentin, E. N. Olson, and D. S. Kohtz, submitted for publication.

REFERENCES

  1. Yaffe, D. (1968) Proc. Natl. Acad. Sci. U. S. A. 61, 477-483 [Medline] [Order article via Infotrieve]
  2. Buckingham, M. (1994) Cell 78, 15-21 [Medline] [Order article via Infotrieve]
  3. Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. N., and Klein, W. H. (1993) Nature 364, 501-506 [CrossRef][Medline] [Order article via Infotrieve]
  4. Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., Nonaka, I., and Nabeshima, Y. (1993) Nature 364, 532-535 [CrossRef][Medline] [Order article via Infotrieve]
  5. Braun, T., Rudnicki, M. A., Arnold, H. H., and Jaenisch, R. (1992) Cell 71, 369-382 [Medline] [Order article via Infotrieve]
  6. Rudnicki, M. A., Braun, T., Hinuma, S., and Jaenisch, R. (1992) Cell 71, 383-390 [Medline] [Order article via Infotrieve]
  7. Rudnicki, M. A., Schnegelsberg, P. N., Stead, R. H., Braun, T., Arnold, H. H., and Jaenisch, R. (1993) Cell 75, 1351-1359 [Medline] [Order article via Infotrieve]
  8. Davis, R. L., Weintraub, H., and Lassar, A. B. (1987) Cell 51, 987-1000 [Medline] [Order article via Infotrieve]
  9. Wright, W. E., Sassoon, D. A., and Lin, V. K. (1989) Cell 56, 607-617 [Medline] [Order article via Infotrieve]
  10. Braun, T., Buschhausen Denker, G., Bober, E., Tannich, E., and Arnold, H. H. (1989) EMBO J. 8, 701-709 [Abstract]
  11. Braun, T., Bober, E., Winter, B., Rosenthal, N., and Arnold, H. H. (1990) EMBO J. 9, 821-831 [Abstract]
  12. Miner, J. H., and Wold, B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1089-1093 [Abstract]
  13. Rhodes, S. J., and Konieczny, S. F. (1989) Genes Dev. 3, 2050-2061 [Abstract]
  14. Olson, E. N., and Klein, W. H. (1994) Genes Dev. 8, 1-8 [CrossRef][Medline] [Order article via Infotrieve]
  15. Konigsberg, I. W. (1963) Science 140, 1273-1284
  16. Clegg, C. H., Linkhart, T. A., Olwin, B. B., and Hauschka, S. D. (1987) J Cell Biol. 105, 949-956 [Abstract]
  17. Olson, E. N. (1992) Dev. Biol. 154, 261-272 [Medline] [Order article via Infotrieve]
  18. Linkhart, T. A., Clegg, C. H., and Hauschka, S. D. (1980) J. Supramol. Struct. 14, 483-498 [Medline] [Order article via Infotrieve]
  19. Brennan, T. J., Edmondson, D. G., Li, L., and Olson, E. N. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3822-3826 [Abstract]
  20. Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., and Weintraub, H. (1990) Cell 61, 49-59 [Medline] [Order article via Infotrieve]
  21. Bengal, E., Ransone, L., Scharfmann, R., Dwarki, V. J., Tapscott, S. J., Weintraub, H., and Verma, I. M. (1992) Cell 68, 507-519 [Medline] [Order article via Infotrieve]
  22. Li, L., Chambard, J. C., Karin, M., and Olson, E. N. (1992) Genes Dev. 6, 676-689 [Abstract]
  23. Li, L., Zhou, J., James, G., Heller Harrison, R., Czech, M. P., and Olson, E. N. (1992) Cell 71, 1181-1194 [Medline] [Order article via Infotrieve]
  24. Rao, S. S., and Kohtz, D. S. (1995) J. Biol. Chem. 270, 4093-4100 [Abstract/Free Full Text]
  25. Skapek, S. X., Rhee, J., Spicer, D. B., and Lassar, A. B. (1995) Science 267, 1022-1024 [Medline] [Order article via Infotrieve]
  26. Zhou, J., and Olson, E. N. (1994) Mol. Cell. Biol. 14, 6232-6243 [Abstract]
  27. Goldhamer, D. J., Brunk, B. P., Faerman, A., King, A., Shani, M., and Emerson, C. P., Jr. (1995) Development 121, 637-649 [Abstract/Free Full Text]
  28. Dalton, S. (1992) EMBO J. 11, 1797-1804 [Abstract]
  29. Nigg, E. A. (1993) Curr. Opin. Cell Biol. 5, 187-193 [Medline] [Order article via Infotrieve]
  30. Nurse, P. (1990) Nature 344, 503-508 [CrossRef][Medline] [Order article via Infotrieve]
  31. Pines, J., and Hunter, T. (1989) Cell 58, 833-846 [Medline] [Order article via Infotrieve]
  32. Jackman, M., Firth, M., and Pines, J. (1995) EMBO J. 14, 1646-1654 [Abstract]
  33. Glotzer, M., Murray, A. W., and Kirschner, M. W. (1991) Nature 349, 132-138 [CrossRef][Medline] [Order article via Infotrieve]
  34. Cogswell, J. P., Godlevski, M. M., Bonham, M., Bisi, J., and Babiss, L. (1995) Mol. Cell. Biol. 15, 2782-2790 [Abstract]
  35. Hwang, A., Maity, A., McKenna, W. G., and Muschel, R. J. (1995) J. Biol. Chem. 270, 28419-28424 [Abstract/Free Full Text]
  36. Blackwell, T. K., and Weintraub, H. (1990) Science 250, 1104-1110 [Medline] [Order article via Infotrieve]
  37. Lassar, A. B., Davis, R. L., Wright, W. E., Kadesch, T., Murre, C., Voronova, A., Baltimore, D., and Weintraub, H. (1991) Cell 66, 305-315 [Medline] [Order article via Infotrieve]
  38. Weintraub, H., Dwarki, V. J., Verma, I., Davis, R., Hollenberg, S., Snider, L., Lassar, A., and Tapscott, S. J. (1991) Genes Dev. 5, 1377-1386 [Abstract]
  39. Gorman, C. M., Merlino, G. T., Willingham, M. C., Pastan, I., and Howard, B. H. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 6777-6781 [Abstract]
  40. Blau, H. M., and Webster, C. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 5623-5627 [Abstract]
  41. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  42. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051 [Medline] [Order article via Infotrieve]
  43. Mitchell, P. J., Wang, C., and Tjian, R. (1987) Cell 50, 847-861 [Medline] [Order article via Infotrieve]
  44. Williams, T., Admon, A., Luscher, B., and Tjian, R. (1988) Genes Dev. 2, 1557-1569 [Abstract]
  45. Dynan, W. S., and Tjian, R. (1983) Cell 35, 79-87 [Medline] [Order article via Infotrieve]
  46. Gidoni, D., Dynan, W. S., and Tjian, R. (1984) Nature 312, 409-413 [Medline] [Order article via Infotrieve]
  47. Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. (1987) Cell 51, 1079-1090 [Medline] [Order article via Infotrieve]
  48. Kadonaga, J. T., Courey, A. J., Ladika, J., and Tjian, R. (1988) Science 242, 1566-1570 [Medline] [Order article via Infotrieve]
  49. van Huijsduijnen, R. A. H., Bollekens, J., Dorn, A., Benoist, C., and Mathis, D. (1987) Nucleic Acids Res. 15, 7265-7282 [Abstract]
  50. van Huijsduijnen, R. H., Li, X. Y., Black, D., Matthes, H., Benoist, C., and Mathis, D. (1990) EMBO J. 9, 3119-3127 [Abstract]
  51. Weintraub, H., Davis, R., Lockshon, D., and Lassar, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5623-5627 [Abstract]
  52. Gregor, P. D., Sawadogo, M., and Roeder, R. G. (1990) Genes Dev. 4, 1730-1740 [Abstract]
  53. Lemaigre, F. P., Courtois, S. J., Lafontaine, D. A., and Rousseau, G. G. (1989) Eur. J. Biochem. 181, 555-561 [Abstract]
  54. Henthorn, P., Kiledjian, M., and Kadesch, T. (1990) Science 247, 467-470 [Medline] [Order article via Infotrieve]
  55. Murre, C., McCaw, P. S., and Baltimore, D. (1989) Cell 56, 777-783 [Medline] [Order article via Infotrieve]
  56. Murre, C., Voronova, A., and Baltimore, D. (1991) Mol. Cell. Biol. 11, 1156-1160 [Medline] [Order article via Infotrieve]
  57. Nelson, C., Shen, L. P., Meister, A., Fodor, E., and Rutter, W. J. (1990) Genes Dev. 4, 1035-1043 [Abstract]
  58. Weintraub, H., Tapscott, S. J., Davis, R. L., Thayer, M. J., Adam, M. A., Lassar, A. B., and Miller, A. D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 5434-5438 [Abstract]
  59. Ruezinsky, D., Beckmann, H., and Kadesch, T. (1991) Genes Dev. 5, 29-37 [Abstract]
  60. Murre, C., McCaw, P. S., Vaessin, H., Caudy, M., Jan, L. Y., Jan, Y. N., Cabrera, C. V., Buskin, J. N., Hauschka, S. D., Lassar, A. B., Weintraub, H., and Baltimore, D. (1989) Cell 58, 537-544 [Medline] [Order article via Infotrieve]
  61. Weintraub, H., Genetta, T., and Kadesch, T. (1994) Genes Dev. 8, 2203-2211 [Abstract]
  62. Davis, R. L., Cheng, P. F., Lassar, A. B., and Weintraub, H. (1990) Cell 60, 733-746 [Medline] [Order article via Infotrieve]
  63. Lassar, A. B., Skapek, S. X., and Novitch, B. (1994) Curr. Opin. Cell. Biol. 6, 788-794 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.